Alloplex Biotherapeutic’s SUPLEXA cells represent a new type of autologous adoptive cellular therapy for cancer

SUPLEXA immunotherapeutic cells are derived by activation, differentiation, and expansion of cancer patient peripheral blood mononuclear cells (PBMCs) by an ‘training’ melanoma tumor cell line that has been engineered to express multiple immunomodulatory factors. SUPLEXA cells generated by our manufacturing process develop into potent and broadly cancer reactive cells that do not damage normal cells or tissues. Our SUPLEXA cellular therapeutic approach is currently being tested in a Phase 1 metastatic cancer clinical trial in Australia. The majority of the first 20 metastatic cancer patients, which had progressive disease (PD) have shown disease stabilization without any drug related adverse events. Furthermore, several patients have reported improved quality of life. In addition to tumor size measurements, we performed comprehensive, longitudinal single-cell PBMC profiling and plasma cytokine measurements of enrolled patients as a measure of changes in immune health over time. Patients with stable disease (SD) showed marked changes in specific immune cell type abundances and altered circulating cytokines that are indicative of improved immune health. These laboratory observations serve as pharmacodynamic markers of SUPLEXA activity, which will be used clinically to optimize the dosing schedule and select the target cancer patient population most likely to benefit. The lack of negative adverse event observations will facilitate the developmental path for SUPLEXA cellular therapy with feasibility to explore combinations with other cancer therapies without concern about compounding side effects. Our basic insights into the biology of SUPLEXA cells strongly suggest that our SUPLEXA cellular therapy approach is a novel and multivalent personalized cellular therapy with potential for treating multiple types of cancers

Please enter your email to access content Read now